106 phenotypes from 12 alleles in 11 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Ppardtm1.1Rev/Ppardtm1.1Rev Not Specified	abnormal adipose tissue morphology	J:73557
	abnormal fat cell morphology	J:73557
	abnormal placenta development	J:73557
	decreased abdominal fat pad weight	J:73557
	decreased interscapular fat pad weight	J:73557
	decreased mesenteric fat pad weight	J:73557
	decreased placental labyrinth size	J:73557
	decreased subcutaneous adipose tissue amount	J:73557
	embryonic growth retardation	J:73557
	embryonic lethality during organogenesis, incomplete penetrance	J:73557
Ppardtm1Dgen/Ppard+ involves: 129P2/OlaHsd * C57BL/6	decreased thermal nociceptive threshold	J:101679
Ppardtm1Dgen/Ppardtm1Dgen involves: 129P2/OlaHsd * C57BL/6	dilated lateral ventricle	J:101679
	embryonic lethality during organogenesis, incomplete penetrance	J:101679
Ppardtm1Dsvg/Ppardtm1Dsvg involves: 129S2/SvPas	abnormal placenta development	J:107381
	embryonic growth retardation	J:107381
	embryonic lethality during organogenesis, incomplete penetrance	J:107381
	postnatal growth retardation	J:107381
	reduced fertility	J:107381
Ppardtm1Dsvg/Ppardtm1Dsvg involves: 129S2/SvPas * C57BL/6	abnormal bone ossification	J:219677
	abnormal circulating protein level	J:219677
	abnormal compact bone morphology	J:219677
	abnormal compact bone volume	J:219677
	abnormal response to exercise	J:219677
	decreased aerobic running capacity	J:219677
	decreased bone mineral density	J:219677
	decreased bone mineral density of femur	J:219677
	decreased bone stiffness	J:219677
	decreased bone strength	J:219677
	decreased bone volume	J:219677
	decreased energy dissipated prior to femur fracture	J:219677
	decreased lean body mass	J:219677
	decreased skeletal muscle mass	J:219677
	impaired glucose tolerance	J:219677
	impaired osteoblast differentiation	J:219677
	increased bone marrow adipose tissue amount	J:219677
	increased bone resorption	J:219677
	increased osteoclast cell number	J:219677
	muscle weakness	J:219677
Ppardtm1Jps/Ppardtm1Jps involves: 129/Sv * C57BL/6N	abnormal brain morphology	J:63040
	abnormal energy expenditure	J:63040
	abnormal gonadal fat pad morphology	J:63040
	abnormal lipid level	J:76564
	abnormal myelination	J:63040
	decreased body size	J:63040
	decreased brain size	J:63040
	decreased fetal size	J:63040
	decreased liver cholesterol level	J:89827
	decreased liver triglyceride level	J:89827
	epidermal hyperplasia	J:63040
	increased circulating triglyceride level	J:89827
	increased circulating VLDL cholesterol level	J:89827
	increased fatty acids level	J:89827
	increased incidence of tumors by chemical induction	J:90217, J:90337
	increased intestinal adenocarcinoma incidence	J:90217
	increased sebaceous gland adenoma incidence	J:90337
	increased skin papilloma incidence	J:90337
	increased skin tumor incidence	J:90337
	increased total body fat amount	J:89827
	increased tumor incidence	J:90337
	intestine polyps	J:90217
	prenatal lethality	J:63040
	skin inflammation	J:63040
Ppardtm1Mtz/Ppardtm1Mtz Tg(KRT14-cre)1Ipc/0 involves: C57BL/6 * SJL	abnormal epidermal layer morphology	J:109090
	abnormal keratinocyte morphology	J:109090
	abnormal skin condition	J:109090
	abnormal skin morphology	J:109090
	decreased cholesterol level	J:109090
Ppardtm1Rev/Ppardtm1Rev Tg(Fabp4-cre)1Rev/0 Not Specified	normal adipose tissue phenotype	J:73557
Ppardtm1Wwah/Ppard+ Not Specified	abnormal keratinocyte adhesion	J:71272
	delayed wound healing	J:71272
	increased keratinocyte proliferation	J:71272
	thick epidermis	J:71272
Ppardtm1Wwah/Ppardtm1Wwah Not Specified	abnormal hair follicle development	J:96826
	abnormal hair follicle peg morphology	J:96826
	decreased keratinocyte proliferation	J:96826
	increased keratinocyte apoptosis	J:96826
	prenatal lethality, incomplete penetrance	J:71272
	thin hypodermis	J:96826
	thin skin	J:96826
	underdeveloped hair follicles	J:96826
Ppardtm1Yjj/Ppardtm1Yjj involves: 129	abnormal epidermis stratum corneum morphology	J:182124
	abnormal stratum corneum lipid matrix formation	J:182124
Ppardtm2Rev/Ppardtm2Rev involves: 129S4/SvJae	abnormal extraembryonic tissue morphology	J:105694
	prenatal lethality, complete penetrance	J:105694
Rgs9tm1.1(cre)Yql/Rgs9+ Tg(CAG-Ppard*E411P)#Als/0 B6J.Cg-Rgs9tm1.1(cre)Yql Tg(CAG-Ppard*E411P)#Als	abnormal medium spiny neuron morphology	J:233176
	abnormal motor capabilities/coordination/movement	J:233176
	decreased grip strength	J:233176
	impaired coordination	J:233176
	kyphosis	J:233176
	limb grasping	J:233176
	neurodegeneration	J:233176
Tg(CAG-Ppard*E411P)#Als/0 Tg(Nes-cre)1Kln/0 B6J.Cg-Tg(Nes-cre)1Kln Tg(CAG-Ppard*E411P)#Als	abnormal basal ganglion morphology	J:233176
	abnormal cerebral cortex morphology	J:233176
	abnormal mitochondrial ATP synthesis coupled electron transport	J:233176
	abnormal motor capabilities/coordination/movement	J:233176
	abnormal response to novel object	J:233176
	decreased body weight	J:233176
	decreased brain size	J:233176
	decreased dopaminergic neuron number	J:233176
	decreased exploration in new environment	J:233176
	decreased grip strength	J:233176
	decreased mitochondrial size	J:233176
	decreased neuron number	J:233176
	gliosis	J:233176
	impaired coordination	J:233176
	kyphosis	J:233176
	limb grasping	J:233176
	neurodegeneration	J:233176
	short stride length	J:233176
Tg(Ckm-Ppard)MEDpk/0 involves: C57BL/6 * CBA	abnormal muscle cell glucose uptake	J:129848
	impaired glucose tolerance	J:129848
	insulin resistance	J:129848
Tg(Myh6-Ppard)HEDpk/0 involves: C57BL/6 * CBA	abnormal response to cardiac infarction	J:130750
	normal cardiovascular system phenotype	J:130750
	decreased cardiac muscle contractility	J:130750
	decreased myocardial infarct size	J:130750
	increased cardiac muscle cell glucose uptake	J:130750
	increased cardiac muscle glycogen level	J:130750